New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
07:03 EDTBDSI, ENDPBioDelivery Sciences announces Buprenorphine study to be locked by Endo Health
The database for the BEMA Buprenorphine Phase 3 clinical study in opioid naive patients with chronic pain is expected to be locked shortly by BDSI's partner, Endo Pharmaceuticals. This event is expected to trigger a $10M milestone payment from Endo per the licensing and development agreement signed in January 2012. In addition, based on recruitment rates in a second Phase 3 clinical study of BEMA Buprenorphine in an opioid experienced patient group, the database for this trial is anticipated to be locked by mid-2014, with results following shortly thereafter.
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
10:01 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:55 EDTENDPEndo initiated with a Buy at Guggenheim
Subscribe for More Information
October 21, 2014
06:37 EDTENDPEndo pullback brings buying opportunity, says Piper Jaffray
Subscribe for More Information
October 14, 2014
11:23 EDTENDPBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
10:08 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:41 EDTENDPEndo upgraded to Hold from Sell at Cantor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use